Distinguishing COVID-19, Influenza, and the Common Cold
Respiratory illnesses such as COVID-19, influenza, and the common cold are caused by viruses that primarily target the upper and lower respiratory tracts. While they result in similar key symptoms like cough, fever, and fatigue, there are some distinguishing features in terms of severity, duration of illness, potential for complications, and transmission dynamics. This article explores the differences and similarities between these three common viral respiratory infections to inform evidence-based diagnosis and decision-making, especially with overlapping symptoms.
Etiology and Transmission
COVID-19 is caused by infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Influenza results from infection by an influenza virus – usually type A or B. The common cold can be caused by over 200 different viral types, predominantly rhinoviruses.
All three viruses spread through respiratory droplets or aerosols produced when an infected person talks, coughs, or sneezes in close contact. Droplets carry the viral particles which can then enter a new host primarily through the eyes, nose or mouth. COVID-19 and influenza also spread through touching contaminated surfaces followed by face touching. Their basic reproduction number (R0) is around 2-3, meaning each infected person spreads it to 2-3 others on average. The common cold spreads rapidly during the fall-winter season but has a low R0.
Symptoms and Severity
The most common early symptoms are headache, fever, body ache, sore throat and cough, making early clinical distinction difficult. However, there are some notable differences in severity and complications.
Influenza comes on suddenly with high fever, chills, headache and body ache. Cold symptoms appear more gradually and include stuffy nose, sneezing and sore throat. COVID-19 has a wider range – from very mild to severe illness and death in some cases. Key symptoms are cough, shortness of breath, fatigue, fever and loss of taste/smell.
While the common cold is generally mild and self-limiting, influenza and COVID-19 can progress to viral pneumonia, respiratory failure and death in high-risk groups like the elderly and those with underlying conditions. COVID-19 has a higher risk of severe disease.
The case fatality rate is <0.1% for colds, around 0.1% for flu and estimated at 1-2% for COVID-19. The infection fatality rate (IFR) is likely lower due to asymptomatic cases being missed. Reinfection is possible with colds due to many viral strains. Flu reinfects due to antigenic drift. Immunity against COVID-19 appears to wane too, allowing reinfections.
Diagnosis
Physical examination and medical history can provide initial clues but laboratory testing is needed for confirmation since the clinical presentation overlaps considerably. Molecular techniques like PCR detect genes of the infecting virus and are the gold standard. Antigen detection kits are faster but less sensitive. Antibody tests determine past infection but are not useful for early diagnosis.
A PCR swab from the nasopharynx is the common specimen for testing respiratory viruses. Influenza PCR has a high specificity of 95-100% and is useful for confirming diagnosis in hospitalized patients. However, test sensitivity is only 60-80% by the time patients present for care.
For suspected COVID-19, the CDC recommends a nucleic acid amplification (NAAT/PCR) or antigen test with confirmation of a negative result by PCR if an antigen test was used first. Chest imaging like CT scans and X-rays can also detect characteristic patterns of lung involvement indicitive of COVID-19 pneumonia.
Treatment
There are no proven effective therapies for the common cold; treatment aims to relieve symptoms. Antiviral drugs like oseltamivir (Tamiflu) or zanamivir (Relenza) can reduce severity and duration of influenza if given early, especially for those at high risk of complications.
For COVID-19, the antiviral remdesivir appears to shorten recovery time in severely ill patients. Steroids help control lung inflammation in severe disease. Supportive therapy is the mainstay– managing fever, oxygenation and organ dysfunction. Prevention via vaccination is key for influenza and COVID-19. The influenza vaccine composition changes annually based on circulating strains. COVID-19 vaccines provide protection from severe illness but immunity wanes over months.
Prevention and Control
Non-pharmaceutical interventions help reduce transmission of all three respiratory viruses: face masks, improved ventilation and filtration indoors, hand hygiene, surface disinfection, isolation of cases, and social distancing. Widespread vaccination is the long-term solution, conferred by herd immunity.
In conclusion, while COVID-19, influenza and the common cold have overlapping clinical features, COVID-19 causes more severe and fatal illness. Diagnostic testing is crucial with emerging respiratory outbreaks of unknown origin to guide appropriate treatment and pandemic control measures.
About The Author
